Abstract
In January 2010, liraglutide (Victoza; Novo Nordisk) — an injectable glucagon-like peptide 1 receptor agonist — was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Signaling pathways in obesity: mechanisms and therapeutic interventions
Signal Transduction and Targeted Therapy Open Access 28 August 2022
-
Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
Cardiovascular Drugs and Therapy Open Access 13 November 2019
-
Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides
Scientific Reports Open Access 11 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).
Lovshin, J. A. & Drucker, D. J. Incretin-based therapies for type 2 diabetes mellitus. Nature Rev. Endocrinol. 5, 262–269 (2009).
Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664–1669 (2000).
US Food and Drug Administration. FDA labelling information — Victoza (liraglutide). FDA website [online], (2010).
Garber, A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473–481 (2009).
Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84–90 (2009).
Marre, M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet. Med. 26, 268–278 (2009).
Russell-Jones, D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52, 2046–2055 (2009).
Zinman, B. et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32, 1224–1230 (2009).
Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009).
Drucker, D. J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240–1250 (2008).
Drucker, D. J. et al. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits. Diabetes Care 33, 428–433 (2010).
Bunck, M. C. et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32, 762–768 (2009).
Knudsen, L. B. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 4 Mar 2010 (doi: 10.1210/en.2009–1272)
Ban, K. et al. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J. Am. Soc. Hyperten. 3, 245–259 (2009).
IMS MIDAS (IMS Health, 2009).
Vosser, R. Hauber, A. & Gordon, J. D. Europe Equity Research Report (J. P. Morgan, 5 Feb 2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Daniel J. Drucker has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arena Pharmaceuticals Inc., Arisaph Pharmaceuticals Inc., Eli Lilly Inc, GlaxoSmithKline, Hoffman LaRoche Inc, Isis Pharmaceuticals Inc., Merck Research Laboratories, Metabolex Inc., Novartis Pharmaceuticals, Novo Nordisk Inc., Phenomix Inc, and Transition Pharmaceuticals Inc. Mt. Sinai Hospital receives research funding for Dr Drucker's preclinical studies on liraglutide. Neither Dr Drucker or his family members hold stock directly or indirectly in any of these companies.
Rights and permissions
About this article
Cite this article
Drucker, D., Dritselis, A. & Kirkpatrick, P. Liraglutide. Nat Rev Drug Discov 9, 267–268 (2010). https://doi.org/10.1038/nrd3148
Issue Date:
DOI: https://doi.org/10.1038/nrd3148
This article is cited by
-
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Drugs (2024)
-
Recent developments of automated flow chemistry in pharmaceutical compounds synthesis
Journal of Flow Chemistry (2023)
-
Signaling pathways in obesity: mechanisms and therapeutic interventions
Signal Transduction and Targeted Therapy (2022)
-
Advances in oral peptide therapeutics
Nature Reviews Drug Discovery (2020)
-
Novel Modified GLP-1 Derivatives with Prolonged Glucose-Lowering Ability In Vivo
International Journal of Peptide Research and Therapeutics (2020)